Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 7;10(3):146.
doi: 10.3390/diagnostics10030146.

Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives

Fulvio Borella  1 , Eleonora Ghisoni  2   3 , Gaia Giannone  2   3 , Stefano Cosma  1 , Chiara Benedetto  1 , Giorgio Valabrega  2   3 , Dionyssios Katsaros  1
Affiliations
Review

Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives

Fulvio Borella et al. Diagnostics (Basel). .

Abstract

Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological cancers. Despite improvements in medical treatments, the prognosis for EOC remains poor, and there is an urgent need for new therapeutic strategies. Immune checkpoint inhibitors (CPIs) have dramatically improved survival of several cancers and are under evaluation in OC. Unfortunately, CPIs have shown globally unsatisfactory results. The aim of this manuscript is to critically review the results from early-phase trials with CPIs in terms of safety and activity, discuss the possible reasons for disappointing results and the new therapeutic approaches to improve patient outcomes.

Keywords: Ovarian cancer; biomarkers; clinical trials; immune checkpoint inhibitors; immunotherapy; safety.

PubMed Disclaimer

Conflict of interest statement

G Valabreg has received personal fees from Roche, AstraZeneca, Tesaro, PharmaMar and Amgen. The remaining authors have no conflicts of interest to declare.

References

    1. American Cancer Society . Cancer Facts & Figures 2020. American Cancer Society; Atlanta, GA, USA: 2020. p. 20.
    1. Reid B.M., Permuth J.B., Sellers T.A. Epidemiology of ovarian cancer: A review. Cancer Biol. Med. 2017;14:9–32. - PMC - PubMed
    1. Lheureux S., Gourley C., Vergote I., Oza A.M. Epithelial ovarian cancer. Lancet. 2019;23:1240–1253. doi: 10.1016/S0140-6736(18)32552-2. - DOI - PubMed
    1. Ledermann J.A., Raja F.A., Fotopoulou C., Gonzalez-Martin A., Colombo N., Sessa C. ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013;24:24–32. doi: 10.1093/annonc/mdt333. - DOI - PubMed
    1. Hardwick N., Frankel P.H., Cristea M. New approaches for immune directed treatment for ovarian cancer. Curr. Treat. Options Oncol. 2016;17:14. doi: 10.1007/s11864-016-0389-1. - DOI - PubMed